FTI 277

Known as: FTI-277 
 

Topic mentions per year

Topic mentions per year

1995-2017
051019952017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Treatment with statins, inhibitors of HMG-CoA reductase, extends the survival of septic mice. However, the molecular mechanisms… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
Mutations of the ras gene are among the most commonly identified transforming events in human cancers, including multiple myeloma… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2003
2003
The efficacy of tamoxifen in the hormonal therapy of breast cancer is well established, but therapeutic resistance is inevitable… (More)
Is this relevant?
2002
2002
The E-cadherin/catenin cell adhesion system is often down-regulated in epithelial tumors. This is thought to play an important… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Bisphosphonates are the important class of antiresorptive drugs used in the treatment of metabolic bone diseases. Although their… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
PRL-1, -2, and -3 represent a novel class of protein-tyrosine phosphatase with a C-terminal prenylation motif. Although PRL-1 has… (More)
Is this relevant?
1999
1999
In this paper, we describe the effect of the inhibitor of farnesyltransferase (FTI-277) on radioresistance induced by the 24-kDa… (More)
Is this relevant?
1997
1997
The mechanism by which the geranylgeranyltransferase I inhibitor GGTI-298 and the farnesyltransferase inhibitor FTI-277 inhibit… (More)
Is this relevant?
1996
1996
Many tumor cells have a greater resistance to ionizing radiation than their normal counterparts, suggesting that the development… (More)
  • figure 2
  • figure I
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Ras-induced malignant transformation requires Ras farnesylation, a lipid posttranslational modification catalyzed by… (More)
Is this relevant?